Alnylam Pharmaceuticals (United States)

Alnylam Pharmaceuticals is a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics. Based in Cambridge, Massachusetts, Alnylam develops treatments for rare genetic diseases, cardio-metabolic diseases, and hepatic infectious diseases. FDA-approved products include Onpattro (patisiran) and Amvuttra (vutrisiran) for hereditary transthyretin-mediated amyloidosis, Givlaari (givosiran) for acute hepatic porphyria, and Oxlumo (lumasiran) for primary hyperoxaluria type 1. Alnylam’s innovative platform harnesses natural RNAi pathways to silence disease-causing genes.